Zobrazeno 1 - 10
of 10
pro vyhledávání: '"William Kormany"'
Autor:
Anthony S. Stein, Richard A. Larson, Andre C. Schuh, William Stevenson, Ewa Lech-Maranda, Qui Tran, Zachary Zimmerman, William Kormany, Max S. Topp
Publikováno v:
Blood Advances, Vol 2, Iss 13, Pp 1522-1531 (2018)
Abstract: In the phase 3 TOWER study, blinatumomab demonstrated an overall survival benefit over standard-of-care chemotherapy (SOC) in adults with relapsed or refractory (r/r) Philadelphia chromosome–negative (Ph−) B-precursor acute lymphoblasti
Externí odkaz:
https://doaj.org/article/4cae2ee3265043889adec879c99a2cf3
Autor:
Deborah A. Katz, Joan D. Morris, Michael P. Chu, Kevin A. David, Catherine Thieblemont, Nicholas J. Morley, Sharif S. Khan, Andreas Viardot, Alejandro Martín García-Sancho, Guillermo Rodríguez-García, Mariana Bastos-Oreiro, Seung Tae Lee, William Kormany, Yuqi Chen, Hansen L. Wong, Abraham A. Anderson, Yuliya Katlinskaya, Ariel A. Avilion, Tian Dai, Eva González-Barca
Publikováno v:
Leukemia & Lymphoma. 63:2063-2073
This open-label, multicenter, single-arm, phase 2 study assessed the safety and efficacy of blinatumomab consolidation therapy in adult patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL; International Prognostic Index 3-5
Autor:
Hiroaki Goto, Chitose Ogawa, Hiroatsu Iida, Keizo Horibe, Iekuni Oh, Satoru Takada, Yoshinobu Maeda, Hironobu Minami, Yasuhiro Nakashima, Joan D. Morris, William Kormany, Yuqi Chen, Toshihiro Miyamoto
Publikováno v:
Acta Haematologica. 145:592-602
Introduction: The safety and efficacy of blinatumomab, a CD19/CD3 bispecific T-cell engager (BiTE®) molecule, was evaluated in an expansion cohort of the phase 1b/2 study (NCT02412306) in Japanese adult (n = 14) and pediatric (n = 17) patients with
Autor:
Miguel Angel Villalona-Calero, Amita Patnaik, Robert G Maki, Bert O'Neil, James L. Abbruzzese, Ibiayi Dagogo-Jack, Siddhartha Devarakonda, Sara Wahlroos, Chia-Chi Lin, Yutaka Fujiwara, Angelika Terbuch, Sophie Postel-Vinay, Maria-Elisabeth Goebeler, Alfredo Addeo, Hans Prenen, Tobias Arkenau, Adrian G. Sacher, Chunxu Liu, William Kormany, Jordi Rodon Ahnert
Publikováno v:
Journal of Clinical Oncology. 40:TPS3167-TPS3167
TPS3167 Background: Protein arginine methyltransferase 5 (PRMT5) is an emerging target for cancer treatment. MTAP homozygous deletion occurs in 15% of cancers and often coincides with deletion of the tumor suppressor gene CDKN2A, leading to buildup o
Autor:
Guiandre Joseph, Jessica Choudhry, Jacqueline Wright, Deborah Arrindell, Victoria M. Chia, William Kormany, Janet Franklin, Anthony S. Stein, Hamid R. Amouzadeh, Mandy Parson
Publikováno v:
Drug Safety
Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children wit
Autor:
Christin Linderkamp, Rosanna Parasole, Anja Möricke, Thomas Klingebiel, Ondrej Hrusak, Luciana Vinti, William Kormany, Bernd Gruhn, Christian Flotho, Arend von Stackelberg, Concetta Micalizzi, Noemi Mergen, Gerhard Zugmaier, Franco Locatelli, Abeera Mohammad, Vaskar Saha, Cornelia Eckert, J. Morris, Christina Peters, Arnaud Petit, Carmelo Rizzari, Mary Sartor
Publikováno v:
JAMA
Importance: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Objective: To evaluate event-free survival in children with high-ris
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c88001da24b3c717b1097e04b6a32bf
http://hdl.handle.net/10281/339267
http://hdl.handle.net/10281/339267
Autor:
Arnaud Petit, Thomas Klingebiel, Deepali Dilip Pilankar, Concetta Micalizzi, Christian Flotho, William Kormany, Luciana Vinti, J. Morris, Christin Linderkamp, Mary Sartor, Rosanna Parasole, Yi Zeng, Franco Locatelli, Arend von Stackelberg, Carmelo Rizzari, Christina Peters, Vaskar Saha, Ondrej Hrusak, Cornelia Eckert, Anja Moericke, Gerhard Zugmaier, Bernd Gruhn
Publikováno v:
Blood. 138:1231-1231
Background: Children with high-risk 1st relapse B-ALL after frontline chemotherapy have a poor prognosis and are candidates for allogeneic hematopoietic stem cell transplant (alloHSCT) after achieving complete remission (CR). We previously reported t
Autor:
Georg Kreuzbauer, Naufil Alam, Alessandro Rambaldi, Xavier Thomas, Alexandros Spyridonidis, Nicola Stefano Fracchiolla, Anita W. Rijneveld, Cyril Šálek, William Kormany, Abeera Mohammad, Sabina Chiaretti, Isabella Pezzani Grueter
Publikováno v:
Blood. 136:38-39
Background: Blinatumomab is approved for the treatment of adult patients (pts) with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukaemia (R/R Ph- BCP-ALL). We present interim 3-year results of a multi-co
Autor:
Sima Jeha, Peter Bader, Christiane Chen-Santel, Paul-Gerhardt Schlegel, Puneeth Viswagnachar, Jean-Pierre Bourquin, Noemi Mergen, Gerhard Zugmaier, Claudia Rossig, William Kormany, Rupert Handgretinger, Franco Locatelli, Benoit Brethon
Publikováno v:
Blood. 136:24-25
Introduction: The open-label, expanded access study (RIALTO) demonstrated that blinatumomab is efficacious with a manageable safety profile in children with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R BCP-ALL). Blinatumo
Autor:
Andre C. Schuh, Kun Nie, William Stevenson, Anthony S. Stein, William Kormany, Richard A. Larson, Max S. Topp, Ewa Lech-Marańda, Zachary Zimmerman
Publikováno v:
Journal of Clinical Oncology. 35:7032-7032
7032 Background: Blinatumomab (blin), a bispecific T-cell engaging antibody construct, has shown improved overall survival vs SOC in pts with r/r ALL in a randomized phase 3 study ( Haematologica 2016;101:S129). To better evaluate safety, we compared